Introduction
============

Obesity affects more than one‐third of US adults^[@b1]^ and is a major contributor to cardiovascular morbidity and mortality.^[@b2]--[@b3]^ A significant proportion of the cardiovascular risk in obese people is attributed to the development of hypertension,^[@b4]--[@b5]^ which predisposes them to increased risk of atrial fibrillation, coronary heart disease, and stroke.^[@b6]^ Abnormal salt handling is thought to be one of the mechanisms underlying obesity‐related hypertension.^[@b7]--[@b8]^

The natriuretic peptide system, the primary salt‐excreting system in humans, acts as an endogenous antagonist of the renin‐angiotensin‐aldosterone system.^[@b9]^ The primary circulating natriuretic peptides are atrial natriuretic peptide (ANP) and B‐type natriuretic peptide (BNP).^[@b10]^ ANP is produced primarily in the atria, while BNP is derived from both the atria and the ventricles.^[@b10]--[@b11]^

Obese individuals have been found to have lower natriuretic peptide levels in multiple previous studies.^[@b12]--[@b14]^ The finding of lower natriuretic peptides in obese subjects is unexpected because obesity promotes increased plasma volume and hypertension, which are known to lead to left ventricular stress and hypertrophy. These conditions should trigger natriuretic peptide release from the heart. Thus, it has been proposed that obese individuals may have a primary "natriuretic peptide deficiency"^[@b8],[@b13]^ that could contribute to the development of hypertension.

Prior studies have been largely observational, and based on measurement of natriuretic peptide levels collected in individuals with random salt intake. Because natriuretic peptide levels are dependent on loading conditions, more controlled physiologic data are needed. Accordingly, the aim of the current investigation was to study the natriuretic peptide axis in the context of a well‐controlled physiologic stimulus (intravenous saline infusion) in obese, otherwise healthy, individuals. This study design also enabled us to compare the relative effects of weight loss and intravenous saline infusion on circulating natriuretic peptide levels.

Methods
=======

Study Sample
------------

A study research coordinator screened charts for eligibility from a pool of patients who were referred to the weight center of the Massachusetts General Hospital for Roux‐en‐Y gastric bypass surgery. Eligible patients were informed about the details of the research protocol, including the need for 2 saline infusion visits at the Clinical Research Center (CRC) 6 months apart. A study physician investigator verified the medical history of study participants including the use of medications at the time of the saline protocol visit. The subjects were asked to keep a detailed diary of all the food and beverages consumed for the 48 hours prior to each study visit to estimate their nutritional status.

Subjects were excluded if they had any of the following: history of myocardial infarction, heart failure, or left ventricular (LV) ejection fraction \<50%, greater than mild valvular stenosis or regurgitation or any regional wall motion abnormalities by cardiac imaging, chronic renal failure or serum creatinine ≥3.0 mg/dL, atrial fibrillation, diabetes mellitus requiring insulin therapy, systolic blood pressure ≥170 mm Hg or diastolic blood pressure ≥100 mm Hg at the most recent weight center visit, a history of current loop or thiazide diuretic use, a history of obstructive lung disease, or thyroid dysfunction. Female subjects who were pregnant or planned to become pregnant within 6 months were also excluded. The Partners Human Research Committee approved the protocol. All subjects provided informed consent.

Saline Protocol
---------------

Eligible study subjects were admitted after overnight fasting for an outpatient visit at the MGH CRC. Upon admission, two intravenous catheters were placed for phlebotomy and 10 mL/m^2^ of body‐surface area (BSA)/minute normal saline (0.9 mEq/mL) was infused over 2 hours. Blood pressure, heart rate, and oxygen saturation were measured every 20 minutes during the saline infusion. BSA was calculated according to the DuBois algorithm (BSA (in m^2^)=0.20247×height (m)^0.725^×weight (kg)^0.425^). Venous blood was sampled beginning immediately prior to the start of the infusion and at 40, 80, 120, and 180 minutes after the start of the infusion.

The study subjects were brought back to the MGH CRC 6 months after gastric bypass surgery and underwent an identical saline infusion protocol. Subjects were excluded from completing the second saline challenge protocol if they had developed complications of gastric bypass surgery including significant peri‐operative complications (myocardial infarction, persistent atrial fibrillation, sepsis, or gastrointestinal bleeding requiring blood transfusion \>2 units).

Echocardiograms
---------------

Echocardiograms were performed before and after saline infusion at both the baseline and post‐gastric bypass surgery visits. Each subject had four echocardiograms in total during the entire study. Interpretations were made by investigators blinded to clinical status (before or after saline infusion, before or after surgery). The following standard measures were made on two‐dimensional (2D) images in each echocardiogram: interventricular septal and posterior wall thickness (IVS and PWT), left ventricular internal diameter at end‐diastole and end‐systole (LVID, LVIS) and left atrial anteroposterior diameter (LA Dia) in the parasternal view, left ventricular (LV) volumes using a modified Simpson\'s rule (apical 4 chamber and 2 chamber views), mitral inflow E and A velocities and E deceleration time, and mitral annular early diastolic (e′) velocity at the lateral annulus. We did not calculate left atrial volumes due to limited echocardiographic windows in severely obese patients. Estimation of left atrial filling pressure was obtained every 20 minutes during the second hour of the infusion by determining the ratio of the early diastolic mitral inflow velocity to the early diastolic mitral annular velocity.^[@b15]^

Natriuretic Peptide Measurements
--------------------------------

Plasma Nt‐proANP levels were measured by ELISA (proANP 1‐98; Biomedica Medizinprodukte GmbH & Co KG, Austria). Plasma Nt‐proBNP levels were measured using an electrochemiluminescence immunoassay (Elecsys proBNP; Roche, Indianapolis, IN). Mature ANP was measured using an in‐house immunoassay at the Mayo Clinic (Rochester, MN; J. Burnett). Mature BNP was measured by immunoassay (Siemens, New York, NY). Intra‐assay coefficients of variation were \<10% for all assays.

Statistical Analysis
--------------------

Natriuretic peptide measurements were tested for normality and were logarithmically transformed for analysis. We used paired *t* tests to examine the change in BMI, blood pressure, and natriuretic peptides before and after surgery. Mixed effect models using all non‐missing data from 18 study subjects were used to assess the effects of surgery and intravenous saline and their interaction on plasma Nt‐proANP, Nt‐proBNP, and mature ANP and BNP levels, as well as echocardiographic measures. To account for repeated measures for each subject, a spatial power structure for ANP. Nt‐proANP, BNP, and Nt‐proBNP, and a completely general (unstructured) covariance matrix for echocardiographic outcomes were used. None of the interactions terms were significant and *P* values reported are based on models without interaction. A secondary analysis after covariate adjustment for age, sex, and blood pressure was also performed. All analyses were conducted using SAS (Cary, NC). A two‐sided *P*\<0.05 was considered statistically significant for the primary outcome.

Results
=======

We identified 34 patients who met eligibility criteria based on the chart review. Two subjects were excluded because they were found to have diabetes requiring insulin therapy, 1 was excluded because of hypothyroidism, and 13 were excluded because they did not undergo gastric bypass surgery or did not wish to participate. A final study sample of 18 individuals (15 women) was enrolled into the protocol. We had 3 individuals who did not complete the 6‐month follow‐up visit; the sample that completed both visits consisted of 15 individuals (12 women). No subjects were excluded because of peri‐operative complications. [Table 1](#tbl01){ref-type="table"} displays the characteristics of the study sample at baseline and 6 months after surgery. From baseline to 6 months after surgery, subjects had a mean decrease of 27% in body mass index (*P*\<0.0001). There were significant reductions in mean arterial blood pressure (*P*=0.004) and heart rate (*P*\<0.001) after surgery. Only 2 out of 18 subjects were on any class of anti‐hypertensive medications at the pre‐op visit before gastric bypass surgery. At the 6‐month visit, anti‐hypertensive medication was discontinued for one of these subjects, and continued at the same dose for the other subject. The mean±SD volume of saline infusion pre‐bypass was 2.6±0.4 L and post‐bypass was 2.3±0.3 L.

###### 

Baseline Characteristics of the Study Sample Before and After Bypass Surgery

  Characteristics                   Pre‐Bypass Surgery (N=18)   Post‐Bypass Surgery (N=15)   *P* Values
  --------------------------------- --------------------------- ---------------------------- ------------
  Age, y                            43±11                       45±10                        NA
  Female, %                         83                          80                           NA
  Body mass index, kg/m^2^          45±5.4                      33±6.5                       \<0.001
  Systolic blood pressure, mm Hg    117±12                      108±9                        0.05
  Diastolic blood pressure, mm Hg   70±9                        64±12                        0.04
  Mean arterial pressure, mm Hg     86±7                        79±9                         0.004
  Resting heart rate, beats/min     71±10                       65±10                        \<0.001

Values expressed as mean±SD or %, where appropriate. NA indicates not applicable (since these are the same individuals before and after bypass surgery).

Resting plasma concentrations (mean±SEM) of mature ANP and Nt‐proANP were 14±2 pg/mL and 4±0.6 pg/mL at baseline. After gastric bypass surgery, the resting plasma concentrations rose to 24±5 pg/mL and 7±0.7 pg/mL for ANP and Nt‐proANP (increased by 23% and 43%), respectively (*P*=0.016 and 0.008). Absolute concentrations of ANP and Nt‐proANP were higher in individuals after bypass surgery at all acute time points during and after administration of intravenous saline ([Figure 1](#fig01){ref-type="fig"}A and [1](#fig01){ref-type="fig"}B; *P*\<0.001). A secondary analysis, adjusted for age, sex, and mean arterial pressure yielded similar results.

![A, Concentrations of plasma mature ANP levels at baseline and at 40, 80, 120, and 180 minutes after the start of saline infusion. Solid line with squares represents pre‐bypass surgery subjects and dotted line with triangles represents post‐bypass surgery subjects. B, Concentrations of plasma Nt‐proANP levels at baseline and at 40, 80, 120, and 180 minutes after the start of saline infusion. Solid line with squares represents pre‐bypass surgery subjects and dotted line with triangles represents post‐bypass surgery subjects. ANP indicates atrial natriuretic peptide; Nt‐proANP, N‐terminal pro‐ANP.](jah3-4-e001265-g1){#fig01}

Resting plasma concentrations of mature BNP and Nt‐proBNP were 14±3 pg/mL and 42±9 pg/mL before gastric bypass surgery and increased to 32±5 pg/mL and 107±20 pg/mL (increased by 50% and 31%), respectively (*P*=0.0009 and 0.0001) after the surgery. Circulating BNP and Nt‐proBNP concentrations during saline infusion were also higher after surgery compared with before surgery (Figures [2](#fig02){ref-type="fig"}A and [2](#fig02){ref-type="fig"}B; *P*\<0.0001). The saline infusion itself was not associated with an increase in BNP or Nt‐proBNP levels at either visit (*P*=0.65 and 0.60, respectively).

![A, Concentrations of plasma mature BNP levels at baseline and at 40, 80, 120, and 180 minutes after the start of saline infusion. Solid line with squares represents pre‐bypass surgery subjects and dotted line with triangles represents post‐bypass surgery subjects. B, Concentrations of plasma Nt‐proBNP levels at baseline and at 40, 80, 120, and 180 minutes after the start of saline infusion. Solid line with squares represents pre‐bypass surgery subjects and dotted line with triangles represents post‐bypass surgery subjects. BNP indicates B‐type natriuretic peptide; Nt‐proBNP, N‐terminal pro‐BNP.](jah3-4-e001265-g2){#fig02}

Echocardiographic measurements obtained at pre‐ and post‐bypass visits are outlined in [Table 2](#tbl02){ref-type="table"}. Due to limitations in scanning windows and poor image quality, interpretable echocardiograms were obtained in 12 of 15 patients. Transmitral E increased from 76±19 cm/s at pre‐bypass to 83±19 cm/s at the post‐bypass surgery visit while no significant increase was noted in transmitral A. The mean intra‐individual change in transmitral E was 15 cm/s, with 95% confidence interval 3 to 26 cm/s. The increases in transmitral E were significant for the effects of saline (*P*=0.005) and surgery (*P*=0.002). There was also a significant increase in the early diastolic mitral annular velocity e′ (*P*=0.02 for effect of surgery). However, the E/e′ ratio did not change after surgery ([Table 2](#tbl02){ref-type="table"}). Left atrial diameter showed a trend towards decrease at the post‐bypass surgery visit (*P*=0.3).

###### 

Echocardiographic Measures in Obese Subjects Before and After Saline Administration at Pre‐Bypass and Post‐Bypass Surgery Visits

                 Pre‐Bypass   Post‐Bypass   *P* Values                        
  -------------- ------------ ------------- ------------ ---------- --------- -------
  LVEDV, mL      79±13        84±14         80±13        87±14      0.001     0.3
  LVESV, mL      31±7         30±9          31±6         30±7       0.5       0.7
  LVEF, %        60±5.2       65±5.9        61±4.7       66±4.0     0.002     0.4
  SV, mL         47±8         54±9          49±1         57±9       \<0.001   0.1
  CO, L/min      3.3±0.7      4.2±0.7       3.1±0.7      3.7±0.7    \<0.001   0.01
  LA dia (mm)    37.3±2       38.3±2        36.7±4       37.3±2     0.9       0.3
  E, cm/s        76±19.0      89±21         83±19.2      90±17      0.005     0.002
  A, cm/s        64±19        72± 28        64±31        60±13      0.6       0.2
  e′ lat, cm/s   −8.7±2.8     −9.6±2.7      −9.1±2.7     −9.6±2.6   0.09      0.02
  E/e′           −9.9±6       −10.9±7       −10.2±5      −9.5±2.1   0.8       0.4

CO indicates cardiac output; LA dia, left atrial anteroposterior diameter; LVEDV, left ventricular end‐diastolic volume; LVEF, left ventricular ejection fraction; LVESV, left ventricular end‐systolic volume; SV, stroke volume.

At both visits, saline infusion was associated with a significant increase in left ventricular (LV) end‐diastolic volume (*P*=0.001 for saline effect), whereas LV end‐systolic volume was unchanged. Stroke volume and cardiac output increased in response to saline administration at both pre‐ and post‐bypass visits. The effect of saline infusion on cardiac function did not differ before and after surgery (saline×surgery interaction *P* values non‐significant).

Discussion
==========

In summary, we found that weight loss in obese individuals undergoing gastric bypass surgery is associated with higher natriuretic peptide concentrations across a range of loading conditions. This observation is consistent with a higher "set point" of natriuretic peptide levels after weight loss. That these findings are accompanied by improvements in blood pressure, heart rate and echocardiographic diastolic function provides persuasive evidence that the increase in natriuretic peptides with weight loss is "primary" and not secondary to alterations in cardiac structure or function.

It is also notable that the rise in absolute concentrations of ANP and Nt‐proANP after weight loss surgery was comparable to that observed with a 2‐L saline infusion. This observation suggests that the magnitude of obesity‐induced alteration in natriuretic peptide production is physiologically relevant. The slope of the natriuretic peptide response to saline challenge was similar before and after weight loss, suggesting that obesity does not blunt the responsiveness of the natriuretic peptide axis to salt challenge, but rather alters the "set point."

We found that BNP and Nt‐proBNP concentrations were also substantially higher after weight loss surgery, both before and after saline infusion. We did not observe an acute rise in BNP or Nt‐proBNP in the first 3 hours after the saline infusion. The longer half‐lives of BNP and Nt‐proBNP may be one explanation, as these peptides may take longer to peak.^[@b16]^ However, we have noted a similar lack of increase after up to 8 hours of observation.^[@b17]^ Thus, we expect that the changes in BNP associated with surgery are likely to be substantially larger than any change induced by saline, even over longer periods of observation.

Over the same period, we noted an approximately 2‐fold increase in Nt‐proANP levels. Although, BNP co‐localizes with ANP in secretory granules,^[@b18]^ its release may be regulated differently, thereby making the salt loading response more variable.^[@b19]--[@b20]^

Several epidemiologic studies have reported lower circulating natriuretic peptide concentrations in obese individuals.^[@b12],[@b14]^ However, these studies have been observational and confined to a single time point of measurement of natriuretic peptides. To our knowledge, only one previous study has examined the association of obesity with salt‐induced natriuretic peptide concentrations. Licata and colleagues found reduced, salt‐loaded plasma ANP concentrations in 9 obese individuals compared with 10 lean controls.^[@b21]^ They did not examine the influence of weight loss on the natriuretic peptide system. Thus, the present study is the first to provide serial, physiologic data from the same individuals over time.

One proposed mechanism for reduced natriuretic peptide concentrations in obesity is the relative abundance of natriuretic peptide clearance receptors (NPR‐C) in adipose tissue.^[@b13],[@b22]^ Elevated insulin has also been linked to increased expression of NPR‐C in obese subjects.^[@b23]^ On the other hand, plasma Nt‐proANP and Nt‐proBNP levels are reduced in obesity to a comparable degree as the mature peptides. Because the pro‐peptides are not known to bind to NPR‐C, impaired synthesis or secretion likely plays a role in obesity.

Strengths of our study include the serial physiologic assessments before and after bariatric surgery. The gastric bypass procedure ensured a large degree of weight loss (≈27% mean change in BMI), while the administration of normal saline provided an acute stimulus for eliciting acute natriuretic peptide responses. Thus, we were able to compare the relative effects of weight loss and saline infusion, with each individual serving as his or her own control. This study design minimizes confounding from sources of natriuretic peptide variation that might correlate with BMI. We performed the post‐surgical assessment 6 months after surgery to ensure that acute hemodynamic changes from surgery had resolved and patients had attained most of their expected weight loss. Mitral annular early diastolic (e′) velocity at the lateral annulus has been accepted as an index of diastolic function^[@b24]--[@b25]^ and we had significant improvement in e′ suggesting improvement in myocardial relaxation. Our echocardiographic findings are in accordance with the recently published meta‐analysis demonstrating benefits of bariatric surgery on diastolic function.^[@b26]^

There are several limitations of our study. Given the nature of our physiologic protocols, which required two large volume saline infusions in obese patients before and after surgery, our sample size was modest. Nonetheless, we were able to elicit significant relationships of all four natriuretic peptides (ANP, Nt‐proANP, BNP, and Nt‐proBNP) across a variety of salt conditions before and after surgical weight loss. Our study population consisted of primarily females. We do not believe from prior epidemiologic studies looking at resting natriuretic peptide levels in obese individuals^[@b12]^ that having more men in our cohort would have modified our findings. Prior epidemiologic studies do not suggest that gender modifies the association between obesity and natriuretic peptide concentrations. We did not examine short‐term changes in the natriuretic peptide system, as a physiologic assessment immediately after surgery would have been impractical and potentially confounded by post‐operative shifts in volume or nutrition. We also focused on surgical weight loss because weight loss with non‐surgical treatments is less consistent. Thus, we cannot exclude any surgery‐specific effects. Because the saline infusion was indexed to BSA, less saline was given at the post‐weight loss visit. This could have created a "conservative" bias, eg, toward observing a smaller natriuretic peptide response after surgery. Indexing was performed to ensure that the amount of saline relative to plasma volume was relatively constant. Lastly, we did not perform a complete assessment of the renin‐angiotensin‐aldosterone system and the sympathetic nervous system, all of which could also be primarily affected resulting in the observed responses of the natriuretic peptide system after weight loss and/or saline loading.

In summary, our study provides evidence of an alteration in the natriuretic peptide "set point" with weight loss. These findings highlight the potential role of a "natriuretic peptide deficiency" in obesity‐related conditions such as hypertension and heart failure. One can further speculate that reversal of the "natriuretic peptide deficiency" could play a role in the improvement of blood pressure and cardiac function after weight loss.

This study has been supported by the following grants: R01 HL102780, R21 DK092909, and 1 UL1 RR025758‐01 from the National Institutes of Health and the National Center for Research Resources. The research was also supported by a grant from the Foundation LeDucq.

None.

Acknowledgments
===============

The authors thank the Massachusetts General Hospital Clinical Research Center staff.

[^1]: Dr Arora and Dr Reingold contributed equally to this work.

    Deceased.

    This article was handled independently by Hani Jneid, MD, as a guest editor. The editors had no role in the evaluation of the manuscript, or in the decision about its acceptance.
